Category Archives: R&D

Trends in R&D: The Widening Gap between Success and Failure

By Clark Herman | Published: January 31, 2013
The Office of Health Economics (OHE) has released a new study examining drug development costs over the past 30 years. The study finds that out-of-pocket costs to bring a new medicine to market have increased over this period by 600%, success rates from proof of concept to registration have decreased at least twofold since the [...]
Also posted in Emerging Markets, Europe, Strategy, Technology | Tagged | 1 Comment

Amid Flu Epidemic a Focus on Vaccine Innovation

By Reid Paul | Published: January 29, 2013
brightcove.createExperiences();
Also posted in Biotech, Europe, FDA, Manufacturing, Video | Leave a comment

It's Blind Leading the Blind on Companion Diagnostics

By Clark Herman | Published: January 25, 2013
A new report from the Tufts Center for Study of Drug Development (CSDD), confirms that companion diagnostics are an important factor for pharma companies to consider when seeking reimbursement of their drugs. But companies still have a ways to go in allaying the concerns of investors, regulators and payors alike, and fixing this will require [...]
Also posted in FDA, Orphan Drugs, Regulatory, Strategy, Technology | Tagged | Leave a comment

Will "Robust Pipeline" Yield More New Drugs?

By Jill Wechsler | Published: January 21, 2013
Biopharmaceutical companies are touting their huge investment in R&D, which has filled the drug pipeline with more potential first-in-class medicines, including orphan drugs, personalized medicines and new therapies based on novel scientific strategies. A report by the Analysis Group for the Pharmaceutical Research and Manufacturers of America (PhRMA) documents more than 5,000 new medicines in [...]
Also posted in Biotech, FDA, Regulatory, leadership | Tagged , , , , , , | Leave a comment

R&D Trends for 2013: Data Trims, Partnerships, and Emerging Global Players

By Clark Herman | Published: January 14, 2013
The Tufts Center for the Study of Drug Development (CSDD) sees two key trends as increasingly important for pharmaceutical companies to maintain success: eliminating the bane of extraneous data and fostering collaborations with academia and multi-company consortia both as measures of reducing costs and remaining competitive by more quickly and effectively guiding medicines to market. [...]
Also posted in Emerging Markets, IP, Strategy | Tagged , , | 1 Comment